Released May 11, 2020 | SUGAR LAND
en
The Trump administration has announced a new program to develop and distribute an effective COVID-19 vaccine for 300 million U.S. citizens by January 2021. A consortium of private
Numerous challenges remain, the foremost being the lack of understanding of COVID-19, as well as no clear way to choose controls for effective clinical trials. To show that a vaccine works, it must be demonstrated and proven that a large majority of people taking the vaccine would not become infected with SARS CoV-2, compared to controls. Unknowns about the seasonality of the virus are a problem in understanding the number of potential infected people.
Under the agreement, the majority of any financial risk resulting from the effort will be shouldered by the federal government.
Numerous challenges remain, the foremost being the lack of understanding of COVID-19, as well as no clear way to choose controls for effective clinical trials. To show that a vaccine works, it must be demonstrated and proven that a large majority of people taking the vaccine would not become infected with SARS CoV-2, compared to controls. Unknowns about the seasonality of the virus are a problem in understanding the number of potential infected people.
Under the agreement, the majority of any financial risk resulting from the effort will be shouldered by the federal government.
